Celiac disease and risk of myasthenia gravis – nationwide population-based study

BMC Neurology

Table 3 Risk of MG myasthenia gravis in patients with celiac disease. Stratified analyses

Follow-up	HR; 95% CI	P-value	Observed vs. Expected	Person-years	Person-years Incidence rate^a	Excess risk^a	Attributable percentage
Age (yrs)
< 20	2.60; 0.50–13.60	0.257	2 vs 1	147,218	14	8	62
20–39	1.99; 0.40–9.92	0.402	2 vs 1	60,204	33	16	50
40–59	0.58; 0.07–4.58	0.602	1 vs 2	75,119	13	−10	−74
> =60	1.55; 0.33–7.37	0.581	2 vs 1	43,835	46	16	36
Sex
Female	2.28; 0.82–6.37	0.166	5 vs 2	204,000	24	14	56
Male	0.79; 0.18–3.52	0.760	2 vs 3	122,376	16	−4	−26
Calendar period
-1989	1.33; 0.27–6.48	0.726	1 vs 1	85,893	12	3	25
1990–99	1.16; 0.26–5.29	0.848	2 vs 2	161,814	12	2	14
2000-	2.10; 0.57–7.66	0.264	3 vs 1	78,669	38	20	52

^aMyasthenia gravis cases per 1,000,000 person-years in patients with celiac disease

ISSN: 1471-2377